Multi-target therapeutics: when the whole is greater than the sum of the parts. - Wikidata - awgldk - TriplyDB

Multi-target therapeutics: when the whole is greater than the sum of the parts.

Multi-target therapeutics: when the whole is greater than the sum of the parts.

http://www.wikidata.org/entity/Q36697412

about

Discovery and resupply of pharmacologically active plant-derived natural products: A review How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples Update of TTD: Therapeutic Target Database Rational approaches to improving selectivity in drug design Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review Quantitative phenotypic and pathway profiling guides rational drug combination strategies Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery Network connectivity during mergers and growth: Optimizing the addition of a module A ranking method for the concurrent learning of compounds with various activity profiles.Synergy Maps: exploring compound combinations using network-based visualization The antitumor effects of geraniol: Modulation of cancer hallmark pathways (Review)Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Combination therapeutics in complex diseases Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing Mechanistic and functional differentiation of tapentadol and tramadol Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases Search algorithms as a framework for the optimization of drug combinations.Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis Drug inhibition profile prediction for NFκB pathway in multiple myeloma Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir Existence of inverted profile in chemically responsive molecular pathways in the zebrafish liver Mitochondrial pathway mediates the antileukemic effects of Hemidesmus indicus, a promising botanical drug Core site-moiety maps reveal inhibitors and binding mechanisms of orthologous proteins by screening compound libraries A systems biology approach to drug targets in Pseudomonas aeruginosa biofilm Synergism and rules from combination of Baicalin, Jasminoidin and Desoxycholic acid in refined Qing Kai Ling for treat ischemic stroke mice model What does it take to synergistically combine sub-potent natural products into drug-level potent combinations?An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes Controllability in cancer metabolic networks according to drug targets as driver nodes The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity A network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-compound, multi-target, multi-pathway mode of action Pooled screening for synergistic interactions subject to blocking and noise The use of functional chemical-protein associations to identify multi-pathway renoprotectants ASDCD: antifungal synergistic drug combination database Visualization of network target crosstalk optimizes drug synergism in myocardial ischemia Synergistic interaction between selective drugs in cell populations models A Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial Results NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning

P2860

Q22252341-D51E285B-94FE-411F-94C0-40974B4AA14E Q24273350-8EB32F9E-168F-4675-AA01-AA6ECB01CB1F Q24289511-016D2F4E-841E-4DD1-8A7C-10BA9584B225 Q24643206-99D22E3D-5CDA-4A6E-82DA-31375390D01A Q26865357-E7B5E123-B442-4445-A2C8-95432D3009F6 Q27008867-4F8D9A86-D844-4118-9134-F3A2E89266FA Q27021150-F1F00D56-0504-4FD8-AF9F-0E2B700B0C0C Q27144251-9550461A-791C-4144-8F5A-D2AA9F15A33A Q27444499-C8EE7476-633F-49DB-B573-BAAA487149EA Q27902271-E5499ED1-9A47-4483-98C7-43B5789FF5B1 Q27902355-C835A615-828D-4D7D-98EF-E500556483EC Q28067149-6C8DDE2E-EA1A-426E-80F6-263234C43E54 Q28073956-50FCFB43-C834-4945-97AC-72C30EE87430 Q28076891-6BF542B7-AAB0-4F28-853E-867E85342FC5 Q28251171-0BA8D485-A9FC-4370-AEB0-1C6A1FDDFC50 Q28268772-C98F2A34-4C18-46BA-9F89-55B9506256D1 Q28305100-EE3F19BF-3301-40C3-A065-34354987A2E7 Q28388335-646FE94D-9CB3-4344-AA17-B5A1383ABA2D Q28474246-168C2365-02B7-4BDF-B5F1-521149B2BC50 Q28475474-221807E1-E7DA-4D30-983B-C6E8D1D1440C Q28475676-0EB389DA-96F3-4EEC-B778-77FDE602BFED Q28477374-5C9B1E17-C6E6-40C7-9B95-CCDCE02B358D Q28477930-563260B5-7FC0-467C-8728-C06D4B368D94 Q28478180-BB66AE08-9CBF-4CE9-A7D2-3463D47E648B Q28478861-020B0E34-471B-4132-AABA-2A8C9D097B43 Q28481318-E0D210E3-1DBE-4497-92C5-590FC1323A1F Q28482361-A1F5DCBB-55CB-47D0-BAEC-CD8334D4C96D Q28484057-83DABD32-FAD7-47C1-9B11-5A27259262FD Q28485360-3520F16C-09DE-4F3D-AF92-03C29C65BBC8 Q28486030-B7CE9000-78C4-4F64-A7FE-4D8661BA2C8B Q28535399-84FE157C-FA01-4F0F-8840-4EFA4AB9051B Q28538399-711A5AAD-E31F-496D-AAD1-36E6C865B7A4 Q28538646-6D8C959E-80F0-439F-8690-782F84E017A9 Q28538785-F8644407-E513-448F-B85B-B96D5A597F2E Q28538871-41E81F41-F813-41DD-99DD-B8AAE31DEAD6 Q28539135-CDC2B598-3481-4B06-9964-AE04D3B72FFD Q28539539-5B60F002-458B-4812-A66A-8731D0A70214 Q28543382-EE03A235-7179-41C2-B5A4-BDB62CE193A8 Q28547962-34CC12DC-7826-4B46-9EE0-D5CCAC2A850C Q28552626-B5A1D0B1-BD65-468F-8C8C-1A327981A334

P2860

Multi-target therapeutics: when the whole is greater than the sum of the parts.

http://www.wikidata.org/entity/Q36697412

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Multi-target therapeutics: when the whole is greater than the sum of the parts.

@ast

Multi-target therapeutics: when the whole is greater than the sum of the parts.

@en

type

label

Multi-target therapeutics: when the whole is greater than the sum of the parts.

@ast

Multi-target therapeutics: when the whole is greater than the sum of the parts.

@en

prefLabel

Multi-target therapeutics: when the whole is greater than the sum of the parts.

@ast

Multi-target therapeutics: when the whole is greater than the sum of the parts.

@en

P1433

Q36697412-CD8971B6-916D-41C0-9D14-B3CC9B8EB1AA

P1476

Q36697412-1AD9BBC7-8DB8-461E-83A0-A8682D5450DB

P2093

Q36697412-6AD0445D-0C0B-4703-8094-52CC2457C23E

Q36697412-82FDE3F7-E665-4108-8CFE-57BD80C15D07

Q36697412-93B60F2B-34DB-4EDD-8247-3868BBABF2CB

P304

Q36697412-62CD684A-540B-4777-BF1D-7B157B1DBDE1

P31

Q36697412-0EA52B2F-0D68-485D-AB4D-3C8A9EE889AD

P356

Q36697412-F5E27ED3-4C52-41B7-B2A8-B8658938847C

P433

Q36697412-5AD6CC24-18BC-4132-ABB3-A1657C151EB3

P478

Q36697412-E51B94CD-E505-4B78-96E7-4AAE5C87E4DB

P577

Q36697412-1D353FF7-FA49-44E0-8F5A-92D77F2F6649

P5875

Q36697412-1A45E0B2-88FC-4D68-A4AC-76D6A81DC70C

P698

Q36697412-C143911D-C671-454A-A6B1-8E73BF669F29

P356

J.DRUDIS.2006.11.008

P1433

Drug Discovery Today

P1476

Multi-target therapeutics: when the whole is greater than the sum of the parts.

@en

P2093

Curtis T Keith

http://www.w3.org/2001/XMLSchema#string

Grant R Zimmermann

http://www.w3.org/2001/XMLSchema#string

Joseph Lehár

http://www.w3.org/2001/XMLSchema#string

P304

34-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUDIS.2006.11.008

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6601815

http://www.w3.org/2001/XMLSchema#string

P698

17198971

http://www.w3.org/2001/XMLSchema#string